| scholarly article | Q13442814 |
| P2093 | author name string | M Nakamura | |
| T Takahashi | |||
| A Tsuji | |||
| S Sadahiro | |||
| Yukio Ando | |||
| Y Ohashi | |||
| C Tanaka | |||
| K Fujita | |||
| T Sugiyama | |||
| M Sugihara | |||
| K Uehara | |||
| K Shinozaki | |||
| Y Sakata | |||
| S Morita | |||
| T Moriwaki | |||
| W Ichikawa | |||
| Y Takii | |||
| H Miyauchi | |||
| Y Okutani | |||
| K Minamimura | |||
| P2860 | cites work | Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. | Q54241012 |
| The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. | Q54486022 | ||
| Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping | Q79446731 | ||
| Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 | Q80452767 | ||
| UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters | Q80865711 | ||
| Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer | Q83127881 | ||
| Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin | Q83195720 | ||
| Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302) | Q84323662 | ||
| Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms | Q84526175 | ||
| UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer | Q24648015 | ||
| Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics | Q24651239 | ||
| Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 | ||
| Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey | Q33406703 | ||
| Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer | Q33927990 | ||
| Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. | Q33990876 | ||
| Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. | Q34130450 | ||
| Dose-response and trend analysis in epidemiology: alternatives to categorical analysis | Q34294668 | ||
| Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians | Q34629650 | ||
| A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer | Q35108413 | ||
| Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer | Q36915163 | ||
| Clinical and pharmacogenetic factors associated with irinotecan toxicity | Q37192912 | ||
| Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review | Q37345974 | ||
| Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | Q37378223 | ||
| Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians | Q37712297 | ||
| Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis | Q38016943 | ||
| Systemic therapy for metastatic colorectal cancer | Q38109131 | ||
| The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis | Q38202816 | ||
| UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma | Q40426198 | ||
| Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). | Q42937632 | ||
| Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients | Q43273259 | ||
| UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. | Q43714693 | ||
| Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug | Q43804754 | ||
| Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan | Q44097380 | ||
| UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer | Q44922991 | ||
| Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients | Q45009159 | ||
| UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan | Q45263765 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 1709-1716 | |
| P577 | publication date | 2015-04-16 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients | |
| P478 | volume | 112 |
| Q88813314 | Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group |
| Q88651638 | Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients |
| Q33858199 | Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series |
| Q47142559 | Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials |
| Q93186317 | Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX |
| Q60044668 | Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer |
| Q93143934 | Patient factors and their impact on neutropenic events: a systematic review and meta-analysis |
| Q59797795 | Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy |
| Q26778004 | Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update |
| Q37682812 | UGT1A1 polymorphisms in cancer: impact on irinotecan treatment |
Search more.